GENinCode (LON:GENI) Sets New 1-Year Low – Should You Sell?

Shares of GENinCode Plc (LON:GENI) hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as GBX 0.79 and last traded at GBX 0.79, with a volume of 17890465 shares traded. The stock had previously closed at GBX 0.88.

GENinCode Stock Performance

The firm has a 50 day moving average price of GBX 1.03 and a 200-day moving average price of GBX 1.29. The stock has a market capitalization of £5.91 million, a PE ratio of -0.38 and a beta of 0.59. The company has a quick ratio of 15.88, a current ratio of 0.93 and a debt-to-equity ratio of 117.74.

GENinCode (LON:GENI) last released its quarterly earnings data on Monday, June 8th. The company reported GBX (2.08) EPS for the quarter. The business had revenue of GBX 308 million during the quarter. GENinCode had a negative net margin of 185.47% and a negative return on equity of 409.40%. Research analysts expect that GENinCode Plc will post -7.1299999 EPS for the current fiscal year.

About GENinCode

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U.

GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.